PHH3 as an Ancillary Mitotic Marker in Gastrointestinal Stromal Tumors

다국어 초록 (Multilingual Abstract)

Background: Counting mitoses is subjective and time-consuming. The adjunctive diagnostic utility of a recently reported mitotic marker, phosphohistone H3 (PHH3), was investigated in gastrointestinal stromal tumors (GISTs). Methods: We reviewed 77 GISTs for several proliferative indices. These included the mitotic count per 50 high power fields (HPFs), the immunohistochemical Ki-67 labeling index and the immunohistochemical PHH3 mitotic index (MI). For comparison, Spearman’s rank correlation and interclass correlation coefficient were used. Results: Mitotic counts ranged from 0–138 (mean, 7.57±2.34) and the PHH3 MI ranged from 0–126 per 50 HPFs (mean, 9.61±2.27). We found a positive correlation between mitotic counts and PHH3 MI (r=0.810, p<.001). The inter-observer correlation coefficient for three participants was 0.975 for mitotic counts and 0.940 for the PHH3 MI. When using the PHH3 MI instead of mitotic counts in the Armed Forces Institute of Pathology (AFIP) stratification criteria, 10 cases were reclassified. In one patient with a mitotic count of 2 and a PHH3 MI of 6 per 50 HPFs, distant metastasis occurred. Conclusions: In GISTs, the PHH3 MI correlated adequately with mitotic counts and can be used as a useful adjunctive to count mitotic figures efficiently.

참고문헌 (Reference)

1 Schimming TT, "pHH3 immunostaining improves interobserver agreement of mitotic index in thin melanomas" 34 : 266-269, 2012

2 Tsuta K, "Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas" 136 : 252-259, 2011

3 Kim A, "Usefulness of anti‐phosphohistone H3 immunoreactivity to determine mitotic rate in gastrointestinal stromal tumors" 5 : 91-97, 2012

4 Tapia C, "Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity" 30 : 83-89, 2006

5 Filiz G, "The relationship between MIB-1 proliferative activity and mitotic index in gastrointestinal stromal tumors" 54 : 438-441, 2007

6 Ribalta T, "The mitosis-specific antibody anti-phosphohistone-H3(PHH3)facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria" 28 : 1532-1536, 2004

7 Fukushima S, "Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases" 26 : 51-57, 2009

8 Kim YJ, "Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas" 128 : 118-125, 2007

9 Carrillo R, "Prognostic significance of DNA ploidy and proliferative index(MIB-1 index)in gastrointestinal stromal tumors" 28 : 160-165, 1997

10 Bossard C, "Phosphohistone H3 labelling for histoprognostic grading of breast adenocarcinomas and computer-assisted determination of mitotic index" 59 : 706-710, 2006

11 Takahashi H, "Overexpression of phosphorylated histone H3 is an indicator of poor prognosis in gastric adenocarcinoma patients" 14 : 296-302, 2006

12 Hendzel MJ, "Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation" 106 : 348-360, 1997

13 Veras E, "Mitosis-specific marker phospho-histone H3 in the assessment of mitotic index in uterine smooth muscle tumors: a pilot study" 28 : 316-321, 2009

14 Brenner RM, "Immunocytochemical assessment of mitotic activity with an antibody to phosphorylated histone H3 in the macaque and human endometrium" 18 : 1185-1193, 2003

15 Juan G, "Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis" 32 : 71-77, 1998

16 Miettinen M, "Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis" 130 : 1466-1478, 2006

17 Miettinen M, "Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up" 29 : 52-68, 2005

18 Miettinen M, "Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up" 30 : 477-489, 2006

19 Agaimy A, "Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting" 3 : 461-471, 2010

20 Toquet C, "Elevated (> or = 10%) MIB-1 proliferative index correlates with poor outcome in gastric stromal tumor patients: a study of 35 cases" 47 : 2247-2253, 2002

21 Franquemont DW, "Differentiation and risk assessment of gastrointestinal stromal tumors" 103 : 41-47, 1995

22 Fletcher CD, "Diagnosis of gastrointestinal stromal tumors: a consensus approach" 33 : 459-465, 2002

23 Nasr MR, "Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions" 30 : 117-122, 2008

24 Gerdes J, "Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67" 133 : 1710-1715, 1984

25 Corless CL, "Biology of gastrointestinal stromal tumors" 22 : 3813-3825, 2004

26 Nakashima S, "Anti-phosphohistone H3 as an independent prognostic factor in human esophageal squamous cell carcinoma" 33 : 461-467, 2013